Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 2
2022 1
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Radiation to all macroscopic sites of tumor permits greater systemic antitumor response to in situ vaccination.
Carlson PM, Patel RB, Birstler J, Rodriquez M, Sun C, Erbe AK, Bates AM, Marsh I, Grudzinski J, Hernandez R, Pieper AA, Feils AS, Rakhmilevich AL, Weichert JP, Bednarz BP, Sondel PM, Morris ZS. Carlson PM, et al. Among authors: feils as. J Immunother Cancer. 2023 Jan;11(1):e005463. doi: 10.1136/jitc-2022-005463. J Immunother Cancer. 2023. PMID: 36639155 Free PMC article.
Antibody landscape of C57BL/6 mice cured of B78 melanoma via immunotherapy.
Hoefges A, McIlwain SJ, Erbe AK, Mathers N, Xu A, Melby D, Tetreault K, Le T, Kim K, Pinapati RS, Garcia B, Patel J, Heck M, Feils AS, Tsarovsky N, Hank JA, Morris ZS, Ong IM, Sondel PM. Hoefges A, et al. Among authors: feils as. bioRxiv [Preprint]. 2023 Apr 28:2023.02.24.529012. doi: 10.1101/2023.02.24.529012. bioRxiv. 2023. Update in: Front Immunol. 2023 Nov 23;14:1221155. doi: 10.3389/fimmu.2023.1221155. PMID: 36896021 Free PMC article. Updated. Preprint.
CXCR4 allows T cell acute lymphoblastic leukemia to escape from JAK1/2 and BCL2 inhibition through CNS infiltration.
Walker KL, Rinella SP, Hess NJ, Turicek DP, Kabakov SA, Zhu F, Bouchlaka MN, Olson SL, Cho MM, Quamine AE, Feils AS, Gavcovich TB, Rui L, Capitini CM. Walker KL, et al. Among authors: feils as. Leuk Lymphoma. 2021 May;62(5):1167-1177. doi: 10.1080/10428194.2021.1910684. Epub 2021 Apr 11. Leuk Lymphoma. 2021. PMID: 33843403 Free PMC article.
Factors impacting the efficacy of the in-situ vaccine with CpG and OX40 agonist.
Pieper AA, Spiegelman DV, Felder MAR, Feils AS, Tsarovsky NW, Zaborek J, Morris ZS, Erbe AK, Rakhmilevich AL, Sondel PM. Pieper AA, et al. Among authors: feils as. Cancer Immunol Immunother. 2023 Jul;72(7):2459-2471. doi: 10.1007/s00262-023-03433-3. Epub 2023 Apr 5. Cancer Immunol Immunother. 2023. PMID: 37016127 Free PMC article.
KIR/KIR-ligand genotypes and clinical outcomes following chemoimmunotherapy in patients with relapsed or refractory neuroblastoma: a report from the Children's Oncology Group.
Erbe AK, Diccianni MB, Mody R, Naranjo A, Zhang FF, Birstler J, Kim K, Feils AS, Hung JT, London WB, Shulkin BL, Mathew V, Parisi MT, Servaes S, Asgharzadeh S, Maris JM, Park J, Yu AL, Sondel PM, Bagatell R. Erbe AK, et al. Among authors: feils as. J Immunother Cancer. 2023 Feb;11(2):e006530. doi: 10.1136/jitc-2022-006530. J Immunother Cancer. 2023. PMID: 36822669 Free PMC article.
Antibody landscape of C57BL/6 mice cured of B78 melanoma via a combined radiation and immunocytokine immunotherapy regimen.
Hoefges A, McIlwain SJ, Erbe AK, Mathers N, Xu A, Melby D, Tetreault K, Le T, Kim K, Pinapati RS, Garcia BH, Patel J, Heck M, Feils AS, Tsarovsky N, Hank JA, Morris ZS, Ong IM, Sondel PM. Hoefges A, et al. Among authors: feils as. Front Immunol. 2023 Nov 23;14:1221155. doi: 10.3389/fimmu.2023.1221155. eCollection 2023. Front Immunol. 2023. PMID: 38077403 Free PMC article.
Radiation Augments the Local Anti-Tumor Effect of In Situ Vaccine With CpG-Oligodeoxynucleotides and Anti-OX40 in Immunologically Cold Tumor Models.
Pieper AA, Zangl LM, Speigelman DV, Feils AS, Hoefges A, Jagodinsky JC, Felder MA, Tsarovsky NW, Arthur IS, Brown RJ, Birstler J, Le T, Carlson PM, Bates AM, Hank JA, Rakhmilevich AL, Erbe AK, Sondel PM, Patel RB, Morris ZS. Pieper AA, et al. Among authors: feils as. Front Immunol. 2021 Nov 15;12:763888. doi: 10.3389/fimmu.2021.763888. eCollection 2021. Front Immunol. 2021. PMID: 34868010 Free PMC article.
Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial.
Feils AS, Erbe AK, Birstler J, Kim K, Hoch U, Currie SL, Nguyen T, Yu D, Siefker-Radtke AO, Tannir N, Tolaney SM, Diab A, Sondel PM. Feils AS, et al. Cancer Immunol Immunother. 2023 Jul;72(7):2099-2111. doi: 10.1007/s00262-023-03383-w. Epub 2023 Feb 23. Cancer Immunol Immunother. 2023. PMID: 36823323 Free PMC article.